Literature DB >> 25270271

Classics in chemical neuroscience: levodopa.

A Connor Whitfield1, Ben T Moore, R Nathan Daniels.   

Abstract

Levodopa was the first and most successful breakthrough in the treatment of Parkinson's disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa's discovery there was not an effective treatment for managing its symptoms. In 1961, Hornykiewicz pioneered the use of levodopa to enhance dopamine levels in the striatum, significantly improving symptoms in many patients. With the addition of carbidopa in 1974, the frequency of gastrointestinal adverse drug reactions (ADRs) was significantly reduced, leading to the modern treatment of PD. Although levodopa treatment is more than 50 years old, it remains the "gold standard" for PD treatment. This Review describes in detail the synthesis, metabolism, pharmacology, ADRs, and importance of levodopa therapy to neuroscience in the past and present.

Entities:  

Keywords:  Levodopa; Parkinson’s disease; carbidopa; dopamine; dopamine replacement; l-dopa

Mesh:

Substances:

Year:  2014        PMID: 25270271     DOI: 10.1021/cn5001759

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  12 in total

Review 1.  Biological applications of microchip electrophoresis with amperometric detection: in vivo monitoring and cell analysis.

Authors:  Kelci M Schilly; Shamal M Gunawardhana; Manjula B Wijesinghe; Susan M Lunte
Journal:  Anal Bioanal Chem       Date:  2020-04-28       Impact factor: 4.142

2.  Microchip electrophoresis with electrochemical detection for the determination of analytes in the dopamine metabolic pathway.

Authors:  Rachel A Saylor; Erin A Reid; Susan M Lunte
Journal:  Electrophoresis       Date:  2015-06-29       Impact factor: 3.535

3.  Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules.

Authors:  Yan Ding; Xiaoqian Jiang; Yejin Kim
Journal:  Bioinformatics       Date:  2022-05-13       Impact factor: 6.931

4.  Crystal Structures of Cystathionine β-Synthase from Saccharomyces cerevisiae: One Enzymatic Step at a Time.

Authors:  Yupeng Tu; Cheryl A Kreinbring; Megan Hill; Cynthia Liu; Gregory A Petsko; Christopher D McCune; David B Berkowitz; Dali Liu; Dagmar Ringe
Journal:  Biochemistry       Date:  2018-04-13       Impact factor: 3.162

Review 5.  New roles for dopamine in motor skill acquisition: lessons from primates, rodents, and songbirds.

Authors:  A N Wood
Journal:  J Neurophysiol       Date:  2021-05-12       Impact factor: 2.974

Review 6.  Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.

Authors:  Saad Khan; Ruth Hauptman; Libusha Kelly
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-13       Impact factor: 16.459

7.  (13)C/(15)N-Enriched l-Dopa as a Triple-Resonance NMR Probe to Monitor Neurotransmitter Dopamine in the Brain and Liver Extracts of Mice.

Authors:  Hisatsugu Yamada; Tetsuro Kameda; Yu Kimura; Hirohiko Imai; Tetsuya Matsuda; Shinsuke Sando; Akio Toshimitsu; Yasuhiro Aoyama; Teruyuki Kondo
Journal:  ChemistryOpen       Date:  2015-12-30       Impact factor: 2.911

8.  Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease.

Authors:  José A Morales-Garcia; Irene G Salado; Marina Sanz-San Cristobal; Carmen Gil; Ana Pérez-Castillo; Ana Martínez; Daniel I Pérez
Journal:  ACS Omega       Date:  2017-08-30

9.  Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration.

Authors:  Andrey Anatolievich Nedorubov; Alexey Nikitich Pavlov; Natalia Valeryevna Pyatigorskaya; Galina Eduardovna Brkich; Marina Maksimovna Shabalina
Journal:  Open Access Maced J Med Sci       Date:  2019-08-30

10.  Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.

Authors:  Karsten Mueller; Robert Jech; Tommaso Ballarini; Štefan Holiga; Filip Růžička; Fabian A Piecha; Harald E Möller; Josef Vymazal; Evžen Růžička; Matthias L Schroeter
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.